Adding HER1 mAb to chemotherapy or best supportive care improves progression-free survival (moderate to high-quality evidence), the OS (moderate evidence), and tumor response rate (moderate to high-quality evidence) in CRC patients [41]. The gene discussed is EGFR; the disease is colorectal carcinoma.